Mayo Clinic researchers have found that the behaviour of one Alzheimer drug could benefit the field of drug development for other diseases.

Gamma-secretase modulators (GSM), used in testing to treat Alzheimer's, reduce the production of long strands of amyloid beta protein (Abeta) which stick together and can trigger the disease.

Todd Golde, chair of the department of neuroscience at Mayo Clinic, said: "As these compounds lower the amount of the bad, longer sticky Abeta peptides in the brain, they increase the quantity of shorter Abeta peptides that may protect against development of Alzheimer's disease."

These GSMs work on the arrangement of the protein instead of targeting enzymes or cell surface receptors, a discovery which could open up new avenues for the development of drugs treating Alzheimer's and other diseases.

"These agents work on the structure, or substrate, of the protein itself, which had not been believed to be druggable," said Dr Golde.

"This broadens the notion of what drugs can do, and therefore, has wide reaching implication for future drug discovery for many different disorders."

Results from a Phase III clinical trial of the drug tarenflurbil which contains GSMs are expected this summer.

Login and visit the Alzheimer's Disease Knowledge Centre

• Blood sugar warning for the prevention of Alzheimer's 30/12/08
• Brain starvation seems to trigger Alzheimer's, study suggests 29/12/08
• Plans for new Alzheimer's clinics unveiled 24/12/08
• Cardiovascular proteins found to work together to speed up Alzheimer's 22/12/08
• Research looks at strategy games in the prevention of cognitive deterioration 12/12/08

• EBIXA 10mg film-coated tablets - 50.88%
  Treatment of patients with moderately severe to severe Alzheimers disease ...
  
  
• CERETEC - 26.56%
  ... the diagnosis of abnormalities of regional cerebral blood flow, such as those occurring following stroke and other cerebrovascular disease, epilepsy, Alzheimer's Disease and other forms of dementia, transient ischaemic attack, migraine and tumours of the brain. (ii) Technetium [99mTc] Exametazime ...
  
  
• EBIXA 10 mg/g oral drops, solution - 25.26%
  Treatment of patients with moderate to severe Alzheimer's disease ...
  
  
• EXELON Capsules - 25.26%
  Symptomatic treatment of mild to moderately severe Alzheimer's dementia. Symptomatic treatment of mild to moderately severe dementia in patients with idiopathic Parkinson's disease ...
  
  
• CEREZYME 400 U Solution for Infusion - 25.04%
  ... disease and who exhibit clinically significant non-neurological manifestations of the disease. The non-neurological manifestations of Gaucher disease include one or more of the following conditions: • anaemia after exclusion of other causes, such as iron deficiency • thrombocytopenia • bone disease ...
  
  
• CEREZYME 200 U Solution for Infusion - 25.04%
  ... disease and who exhibit clinically significant non-neurological manifestations of the disease. The non-neurological manifestations of Gaucher disease include one or more of the following conditions: • anaemia after exclusion of other causes, such as iron deficiency • thrombocytopenia • bone disease ...